Systematic reviews, meta-analyses and clinical guidelines on MS, NMOSD and MOGAD since 2015. Reviews pool the results of many studies, so they are often the best single summary of what is known. Each one is tagged by software and linked to the medicines, hypotheses and frontiers it covers.
1021Meta-analysis
734Systematic review
24Umbrella review
47Guideline
134Consensus statement
Treatment reviews441Found a benefit
39No benefit found
104Mixed
20Found harm
117Evidence too weak to say
Systematic review · 2026 · Progress in neurobiology
Found a benefit
A review of animal studies found that electrical stimulation of the brain, vagus nerve, or peripheral nerves improved myelin repair in models of multiple sclerosis.
From the abstract
Limited but convergent preclinical evidence suggests ES may enhance remyelination by modulating neuronal and inflammatory pathways.
Tagged by software from the title and abstract. The quote is copied word for word.
Systematic review · 2025 · European journal of neurology
Evidence too weak to say
This review found that several approved MS drugs show signs of repairing myelin in lab studies, but proof in patients is limited because current markers cannot confirm true repair.
From the abstract
Future proof-of-concept clinical trials investigating remyelinating agents in MS should consider combining outcome measures into composite endpoints.
Tagged by software from the title and abstract. The quote is copied word for word.
Systematic review · 2021 · Current pharmaceutical design
This review looks at current MS drugs that calm the immune system and newer drugs being tested to repair damaged myelin, the protective coating on nerves.
From the abstract
However, there are no effective treatments for this disease and the immunomodulatory therapies that currently exist have proven limited success since they only delay the progress of the disease.
Tagged by software from the title and abstract. The quote is copied word for word.
Meta-analysis · 2019 · Scientific reports
Found a benefit
Researchers reviewed animal studies of treatments that might repair myelin, the protective coating on nerves, and found 16 promising options not yet tested in MS trials.
From the abstract
Our meta-analysis also identifies 16 promising therapies which did not enter a clinical trial for MS so far, among them Pigment epithelium-derived factor, Plateled derived growth factor, and Tocopherol derivate TFA-12.
Tagged by software from the title and abstract. The quote is copied word for word.